On April 6, 2017 the United States Judicial Panel On Multidistrict Litigation (JPML) issued this document, “IN RE: FARXIGA (DAPAGLIFLOZIN) PRODUCTS LIABILITY LITIGATION TRANSFER ORDER — MDL No. 2776”, from which we get the following information:
On the basis of the papers filed and the hearing session held, we find that these actions involve common questions of fact, and that centralization of these cases will serve the convenience of the parties and witnesses and promote the just and efficient conduct of this litigation. The actions share factual questions arising from allegations that taking Farxiga or Xigduo XR may result in patients suffering kidney-related injuries, such as diabetic ketoacidosis and kidney damage. The actions thus implicate numerous common issues concerning the development, manufacture, testing, regulatory history, promotion, and labeling of the drugs.
The JPML went on to assign this new Farxiga MDL to Judge Lorna G. Schofield, who will preside over this consolidated litigation in the Southern District of New York federal court.
The FDA is investigating a connection between Farxiga and Xigduo XR — as well as Invokana, Invokamet, Jardiance, Glyxambi, Synjardy, and Qtern — with several different serious side effects, including diabetic ketoacidosis (DKA) and kidney damage.
All of these diabetes drugs are Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors, a new class of diabetes medicines.
We will continue to monitor legal and drug safety developments regarding Farxiga, Xigduo XR, and the several other SLGT2 inhibitor diabetes drugs.
[Read this article in full at original source]____________________________________________
Invokana / Farxiga / Jardiance
Free Case Evaluation
Strictly Confidential, No Obligation.
____________________________________________